Display options
Cite
Huang WT, Lu NM, Hsu WY, et al. CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report. Case Rep Oncol. 2018;11(1):68-74doi: 10.1159/000486568.
Huang, W. T., Lu, N. M., Hsu, W. Y., Chang, S. E., Atkins, A., Mei, R., & Javey, M. (2018). CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report. Case reports in oncology, 11(1), 68-74. https://doi.org/10.1159/000486568
Huang, Wen-Tsung, et al. "CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report." Case reports in oncology vol. 11,1 (2018): 68-74. doi: https://doi.org/10.1159/000486568
Huang WT, Lu NM, Hsu WY, Chang SE, Atkins A, Mei R, Javey M. CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report. Case Rep Oncol. 2018 Feb 01;11(1):68-74. doi: 10.1159/000486568. eCollection 2018. PMID: 29515413; PMCID: PMC5836181.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2018 Feb 01;11(1):68-74. doi: 10.1159/000486568. eCollection 2018.

CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report.

Case reports in oncology

Wen-Tsung Huang, Na-Mi Lu, Wen-Yuan Hsu, Shih-En Chang, Alex Atkins, Rui Mei, Manana Javey

Affiliations

  1. aDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan City, Taiwan.
  2. bDepartment of Pathology, Chi Mei Medical Center, Liouying, Tainan City, Taiwan.
  3. cDepartment of Medical Imaging, Chi Mei Medical Center, Liouying, Tainan City, Taiwan.
  4. dCellMax Taiwan Co. Ltd, Taipei City, Taiwan.
  5. eCellMax Inc., Sunnyvale, California, USA.

PMID: 29515413 PMCID: PMC5836181 DOI: 10.1159/000486568

Abstract

Brain metastases are the most common neurological complications of adult cancers, accounting for more than half of brain tumors. The incidence of brain metastases may be increasing due to improved detection of small lesions by advanced imaging technologies. Given the fast evolution of targeted and immunotherapy regimens, it is essential to serially assess brain malignancies during the disease course for disease monitoring and tailoring of the therapeutic management. For such serial and repetitive assessment, cerebrospinal fluid (CSF) could be the biological fluid of choice to supplement cytology examination for the presence or absence of CNS malignancy, as well as provide extensive information on tumor mutational profile for personalization of treatment. The case described here emphasizes the importance of CSF-ctDNA analysis with the CellMax SMSEQ technology that led to treatment adjustment resulting in clinical remission of the patient.

Keywords: Brain metastases; CNS; CSF; CSF ctDNA; Cancer of unknown primary; CellMax SMSEQ liquid biopsy; Circulating tumor DNA; Liquid biopsy

References

  1. Cancer. 1998 Nov 15;83(10):2181-4 - PubMed
  2. Clin Chem. 2015 Mar;61(3):514-22 - PubMed
  3. Sci Transl Med. 2014 Feb 19;6(224):224ra24 - PubMed
  4. J Neurooncol. 2005 Oct;75(1):5-14 - PubMed
  5. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14 - PubMed
  6. Cancer. 2000 Sep 1;89(5):1095-101 - PubMed
  7. Clin Oncol (R Coll Radiol). 2013 Jan;25(1):36-45 - PubMed
  8. Ann Oncol. 2014 Sep;25(9):1729-35 - PubMed
  9. Handb Clin Neurol. 2012;104:143-8 - PubMed
  10. Neurosurg Focus. 2007 Mar 15;22(3):E7 - PubMed
  11. Respir Investig. 2016 Jan;54(1):14-9 - PubMed
  12. Neoplasma. 1990;37(5):601-6 - PubMed
  13. Curr Treat Options Neurol. 2012 Aug;14(4):416-26 - PubMed
  14. N Engl J Med. 2012 Mar 8;366(10 ):883-892 - PubMed
  15. Nature. 2013 May 2;497(7447):108-12 - PubMed
  16. N Engl J Med. 2013 Mar 28;368(13):1199-209 - PubMed
  17. Case Rep Oncol. 2017 Sep 21;10 (3):857-862 - PubMed

Publication Types